Royalty Pharma Drops $525M for Royalties and Milestones on Sanofi-Licensed MS...
Pictured: Businessmen shaking hands after closing a deal/iStock, Tippapatt Royalty Pharma on Thursday announced that it will acquire royalties and milestones on ImmuNext’s frexalimab, a first-in-class anti-CD40 monoclonal antibody that has been …